TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02658604

Intervention type: OTHER
Intervention: Home medication review by a pharmacist
Description: Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
Study: NCT00418184

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine-Omega3
Description: Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colored cellulose tainted with fishy odor
Description: as arm 1
Study: NCT01870180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeBag
Description: fabric bag of beads which can be heated in a microwave

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00605930

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyruvate, creatine, niacinamide
Description: A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
Study: NCT03022071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
Study: NCT00733330

Intervention type: DEVICE
Group type: OTHER
Intervention: Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique
Description: Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation
Description: Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
Study: NCT02465567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budensonide, Glycopyrronium, and Formoterol Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/9.6 μg
Description: Glycopyrronium, and Formoterol Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 160/14.4/9.6 μg
Description: Budensonide, Glycopyrronium, and Formoterol Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Description: Budensonide, and Formoterol Fumarate
Study: NCT01247948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: navigation assisted spine surgery
Description: navigation assisted pedicle screw placement of spine surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional spine surgery
Description: traditional spine surgery without navigation assist
Study: NCT03965858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - low dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - medium dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - high dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI is to be administered via dry powder inhaler.
Study: NCT02480465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobelitazone 0.5mg
Description: Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
Study: NCT00905125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix®
Description: Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
Study: NCT04460105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching IV infusion on Day 1 and Day 4.
Study: NCT02682602

Intervention type: DEVICE
Intervention: DePuy Synthes total hip arthroplasty

Intervention type: RADIATION
Intervention: Computer tomography
Description: Computer tomography (CT) scan of the hip for creation of bone models.

Intervention type: RADIATION
Intervention: Computer tomography
Description: Computer tomography (CT) scan of the hip for creation of bone models.

Intervention type: RADIATION
Intervention: Fluoroscopy surveillance
Description: Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.

Intervention type: RADIATION
Intervention: Fluoroscopy surveillance
Description: Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.

Intervention type: RADIATION
Intervention: Fluoroscopy surveillance
Description: Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
Study: NCT02070185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 exposures arm
Description: During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 exposures arm
Description: During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period).
Study: NCT03476980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized to Umbilical Cord Milking at birth
Description: The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized to Delayed Cord Clamping at birth
Description: The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
Study: NCT03190486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: During fMRI, healthy volunteers will listen 80 baby's cry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: During fMRI, healthy volunteers will listen 80 baby's cry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: During fMRI, healthy volunteers will listen 80 baby's cry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: During fMRI, healthy volunteers will listen 80 baby's cry.
Study: NCT01223612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified ETDRS laser
Description: Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
Study: NCT00515645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-down tilt and immersion
Description: Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
Study: NCT03482440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate Oral Tablet
Description: 1500mg twice daily for 5 days prior to experimental testing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral table twice daily for 5 days prior to experimental testing
Study: NCT04533607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MAAPS
Description: Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
Study: NCT03131180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Learning Healthcare System
Description: The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
Study: NCT03977649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erenumab
Description: erenumab 140 mg sc every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc every 4 weeks
Study: NCT00536900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advisor-Teller Money Manager
Description: The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FIT
Description: FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
Study: NCT02997800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline infusion
Description: An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline infusion
Description: An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 ml saline infusion
Description: Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
Study: NCT01272336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia (AIH)
Description: Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia (AIH)
Description: Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM-Intermittent Room Air
Description: This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM-Intermittent Room Air
Description: This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
Study: NCT03732105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Surgery-radiotherapy
Description: Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
Study: NCT03050632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N-back
Description: The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: White Bear Task
Description: For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
Study: NCT01288664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF
Description: Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
Study: NCT02778919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin acetate
Study: NCT03083171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrecizumab
Description: At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrecizumab
Description: At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrecizumab
Description: At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
Study: NCT04630938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: intrathecal morphine will be added to anaesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine+lidocaine
Description: local anesthetic will be infused intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous saline infusion
Study: NCT04433910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalesscent Plasma
Description: Transfusion
Study: NCT00309972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (SEQ):
Description: Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm (CON):
Description: concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
Study: NCT00023309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine and adefovir
Description: Lamivudine (100 mg/day) and adefovir (10 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir alone
Description: Adefovir (10 mg/day)
Study: NCT01045096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days